Freenome Initiates PROACT LUNG Clinical Study for the Early Detection of Lung Cancer Using Blood Test Developed on Multiomics Platform

– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer – SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 /PRNewswire/ — Freenome, a privately held company developing multiomics blood tests for early cancer detection, today announced the initiation of its…

Click here to view original post

Advertisement — Advertise with Biotech Networks